SGLT2抑制剂对2型糖尿病心血管和肾脏结局的一级和二级预防:心血管结局试验的系统综述与荟萃分析
BACKGROUND: The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on specific cardiovascular and renal outcomes and whether heterogeneity is based on key baseline characteristics remains undefined.…
要点
- SGLT2抑制剂降低主要不良心血管事件11%,但获益仅见于已患动脉粥样硬化性心血管疾病者。
- SGLT2抑制剂降低心血管死亡或心力衰竭住院风险23%,获益不受动脉粥样硬化性心血管疾病或心衰病史影响。
- SGLT2抑制剂降低肾脏病进展风险45%,基线肾功能越差肾脏获益幅度越小。
核心结论
- SGLT2抑制剂对动脉粥样硬化性主要不良心血管事件有中等获益,且似乎仅限于已患动脉粥样硬化性心血管疾病的患者。
- SGLT2抑制剂在降低心力衰竭住院和肾脏病进展方面具有稳健获益,无论是否已患动脉粥样硬化性心血管疾病或有心力衰竭病史。
研究设计与样本
- 检索PubMed和Embase截至2018年9月24日的文献,采用标准化数据表提取数据,分歧通过共识解决。
- 疗效结局按基线动脉粥样硬化性心血管疾病、心力衰竭和肾功能程度进行分层,合并风险比(HR)及95%CI。
主要发现
- 共纳入3342例主要不良心血管事件、2028例心血管死亡或心力衰竭住院事件和766例肾脏复合结局。
临床怎么用
- 对于已患动脉粥样硬化性心血管疾病的2型糖尿病患者,SGLT2抑制剂可用于降低主要不良心血管事件风险。
- 对于2型糖尿病患者,无论是否已患动脉粥样硬化性心血管疾病或有心力衰竭病史,SGLT2抑制剂可用于降低心力衰竭住院和肾脏病进展风险。
- 基线肾功能较差者使用SGLT2抑制剂时,心力衰竭住院获益更明显,但肾脏病进展获益幅度减小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on specific cardiovascular and renal outcomes and whether heterogeneity is based on key baseline characteristics remains undefined. METHODS: We did a systematic review and meta-analysis of randomised, placebo-controlled, cardiovascular outcome trials of SGLT2i in patients with type 2 diabetes. We searched PubMed and Embase for trials published up to Sept 24, 2018. Data search and extraction were completed with a standardised data form and any discrepancies were resolved by consensus. Efficacy outcomes included major adverse cardiovascular events (myocardial infarction, stroke, or cardiovascular death), the composite of cardiovascular death or hospitalisation for heart failure, and progression of renal disease. Hazard ratios (HRs) with 95% CIs were pooled across trials, and efficacy outcomes were stratified by baseline presence of atherosclerotic cardiovascular disease, heart failure, and degree of renal function. FINDINGS: We included data from three identified trials and 34 322 patients (60·2% with established atherosclerotic cardiovascular disease), with 3342 major adverse cardiovascular events, 2028 cardiovascular deaths or hospitalisation sfor heart failure events, and 766 renal composite outcomes. SGLT2i reduced major adverse cardiovascular events by 11% (HR 0·89 [95% CI 0·83-0·96], p=0·0014), with benefit only seen in patients with atherosclerotic cardiovascular disease (0·86 [0·80-0·93]) and not in those without (1·00 [0·87-1·16], p for interaction=0·0501). SGLT2i reduced the risk of cardiovascular death or hospitalisation for heart failure by 23% (0·77 [0·71-0·84], p<0·0001), with a similar benefit in patients with and without atherosclerotic cardiovascular disease and with and without a history of heart failure. SGLT2i reduced the risk of progression of renal disease by 45% (0·55 [0·48-0·64], p<0·0001), with a similar benefit in those with and without atherosclerotic cardiovascular disease. The magnitude of benefit of SGLT2i varied with baseline renal function, with greater reductions in hospitalisations for heart failure (p for interaction=0·0073) and lesser reductions in progression of renal disease (p for interaction=0·0258) in patients with more severe kidney disease at baseline. INTERPRETATION: SGLT2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atherosclerotic cardiovascular disease. However, they have robust benefits on reducing hospitalisation for heart failure and progression of renal disease regardless of existing atherosclerotic cardiovascular disease or a history of heart failure. FUNDING: None.
引用
- Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018. PMID: 30424892. doi:10.1016/S0140-6736(18)32590-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。